Edwards' TAVR Cuts Risk Of Death Or Heart Failure Events In Moderate Aortic Stenosis Trial

What happened

Edwards Lifesciences reported Phase 3 PROGRESS trial results showing transcatheter aortic valve replacement, a procedure to replace a narrowed heart valve, beat clinical surveillance in moderate aortic stenosis patients at higher risk of disease progression. TAVR cut the combined risk of death or heart failure events by 33% over two years.

Confirmed

Global impact / market context

For Edwards, positive trial data can support wider use of its TAVR devices in patients who are usually only monitored, expanding the pool of treatable patients and supporting future revenue growth. It may also strengthen the company's position when discussing reimbursement and clinical guidelines with regulators and physicians.

Analyst inference

Moderate aortic stenosis patients are traditionally watched with checkups and imaging rather than early intervention, so a proven benefit could shift treatment patterns toward earlier procedures. That would support demand for heart valve devices and related hospital services, while competing device makers face pressure to show similar outcomes.

Analyst inference

What to watch

1. The trial cut heart failure hospitalizations by more than half, from 14.9% with surveillance to 7.4% with TAVR, a result that could influence how doctors weigh early intervention against monitoring. Confirmed
2. Edwards may seek expanded regulatory approval and updated treatment guidelines for TAVR in moderate aortic stenosis, which would widen the eligible patient population and support device sales. Proposed
3. Investors should watch payer coverage decisions and clinician adoption, because reimbursement and doctor willingness to treat earlier determine whether trial benefits translate into higher TAVR procedure volumes and revenue for Edwards. Analyst inference

Evidence

• Original source link unavailable